

# Alain Bitton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1059756/publications.pdf>

Version: 2024-02-01

76  
papers

4,257  
citations

186265

28  
h-index

114465

63  
g-index

76  
all docs

76  
docs citations

76  
times ranked

5115  
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-TNF Therapy and the Risk of Herpes Zoster Among Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 176-182.	1.9	3
2	Serum Analyte Profiles Associated With Crohn's Disease and Disease Location. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 9-20.	1.9	10
3	Fucosyltransferase 2 Mutations Are Associated With a Favorable Clinical Course in Crohn's Disease. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, e166-e170.	2.2	1
4	Increased Prevalence of Myocardial Infarction and Stable Stroke Proportions in Patients with Inflammatory Bowel Diseases in Quebec in 1996-2015. <i>Journal of Clinical Medicine</i> , 2022, 11, 686.	2.4	4
5	IBD-associated G protein-coupled receptor 65 variant compromises signalling and impairs key functions involved in inflammation. <i>Cellular Signalling</i> , 2022, 93, 110294.	3.6	2
6	Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn's Disease With a Loss of Response. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 208-213.	0.3	6
7	Poor Drug Sustainability in Inflammatory Bowel Disease Patients in Clinical Remission on Thiopurine Monotherapy. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1650-1657.	2.3	3
8	No Change in Surgical and Hospitalization Trends Despite Higher Exposure to Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease in the Québec Provincial Database From 1996 to 2015. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 655-661.	1.9	14
9	Crohn's and Colitis Canada's 2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada: A Knowledge Translation Strategy. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S10-S19.	0.3	2
10	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Seniors With IBD. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S34-S39.	0.3	2
11	OUP accepted manuscript. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S20-S26.	0.3	0
12	OUP accepted manuscript. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S40-S45.	0.3	4
13	Patient Perspectives of IBD Care and Services: An Integral Part of a Pan-Canadian Quality Improvement Initiative. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, 229-233.	0.3	4
14	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Health Care Delivery During the Pandemic and the Future Model of Inflammatory Bowel Disease Care. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S61-S67.	0.3	7
15	OUP accepted manuscript. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S1-S9.	0.3	5
16	OUP accepted manuscript. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S27-S33.	0.3	3
17	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Mental Health and Quality of Life. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S46-S53.	0.3	9
18	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines' Biology, Current Evidence and Recommendations. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S54-S60.	0.3	9

#	ARTICLE	IF	CITATIONS
19	Inflammatory Bowel Disease Increases the Risk of Venous Thromboembolism in Children: A Population-Based Matched Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 2031-2040.	1.3	20
20	Anti-Microbial Antibody Response is Associated With Future Onset of Crohn's Disease Independent of Biomarkers of Altered Gut Barrier Function, Subclinical Inflammation, and Genetic Risk. <i>Gastroenterology</i> , 2021, 161, 1540-1551.	1.3	35
21	Patient-Reported Outcome and Clinical Scores Are Equally Accurate in Predicting Mucosal Healing in Ulcerative Colitis: A Prospective Study. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	2.3	4
22	Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-9.	1.9	16
23	Faecal Calprotectin Predicts Endoscopic and Histological Activity in Clinically Quiescent Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 46-52.	1.3	40
24	Development of a Global Rating Scale for Inflammatory Bowel Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2020, 3, 4-16.	0.3	2
25	Do You See What I See? An Assessment of Endoscopic Lesions Recognition and Description by Gastroenterology Trainees and Staff Physicians. <i>Journal of the Canadian Association of Gastroenterology</i> , 2020, 3, 216-221.	0.3	3
26	Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2046-2053.	2.3	11
27	Novel Negative Pressure Box for Aerosol Protection During Upper Endoscopy: A Brief Report on Safety and Barrier Performance. <i>American Journal of Gastroenterology</i> , 2020, 115, 1936-1936.	0.4	2
28	Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease center: Access, resource utilization and outcomes. <i>World Journal of Gastroenterology</i> , 2020, 26, 759-769.	3.3	8
29	The Burden of Anemia Remains Significant over Time in Patients with Inflammatory Bowel Diseases at a Tertiary Referral Center. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 555-559.	0.9	4
30	Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 124-133.	1.9	60
31	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1-13.	1.9	73
32	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1680-1713.	4.4	32
33	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, e1-e34.	0.3	32
34	Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary. <i>Journal of Rheumatology</i> , 2019, 46, 751-754.	2.0	22
35	Clinical Parameters Correlate With Endoscopic Activity of Ulcerative Colitis: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1265-1275.e8.	4.4	36
36	Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data. <i>Gastroenterology</i> , 2019, 156, 1345-1353.e4.	1.3	273

#	ARTICLE	IF	CITATIONS
37	Risk of Malignant Cancers in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1302-1310.	1.3	19
38	High Adherence to Surveillance Guidelines in Inflammatory Bowel Disease Patients Results in Low Colorectal Cancer and Dysplasia Rates, While Rates of Dysplasia are Low Before the Suggested Onset of Surveillance. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1343-1350.	1.3	13
39	Inflammatory bowel disease patient perceptions of diagnostic and monitoring tests and procedures. <i>BMC Gastroenterology</i> , 2019, 19, 30.	2.0	21
40	Selection of Quality Indicators in IBD: Integrating Physician and Patient Perspectives. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 403-409.	1.9	25
41	High-Dose Infliximab Rescue Therapy for Hospitalized Acute Severe Ulcerative Colitis Does Not Improve Colectomy-Free Survival. <i>Digestive Diseases and Sciences</i> , 2019, 64, 518-523.	2.3	16
42	Harmonization of quality of care in an IBD center impacts disease outcomes: Importance of structure, process indicators and rapid access clinic. <i>Digestive and Liver Disease</i> , 2019, 51, 340-345.	0.9	12
43	Reply to Letter on: "Risk Factors Associated With <i>Clostridium difficile</i> Infection in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis". <i>Journal of Crohn's and Colitis</i> , 2019, 13, 536-537.	1.3	0
44	Herpes Zoster Incidence in Inflammatory Bowel Disease Patients: A Population-Based Study. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 914-918.	1.9	25
45	Risk Factors Associated with <i>Clostridium difficile</i> Infection in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 27-38.	1.3	49
46	Maladaptive coping, low self-efficacy and disease activity are associated with poorer patient-reported outcomes in inflammatory bowel disease. <i>Saudi Journal of Gastroenterology</i> , 2019, 25, 159.	1.1	27
47	Therapeutic Drug Monitoring Guides the Management of Crohn's Patients with Secondary Loss of Response to Adalimumab. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1531-1538.	1.9	34
48	Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. <i>BMJ: British Medical Journal</i> , 2018, 360, k872.	2.3	89
49	Quality of care indicators in inflammatory bowel disease in a tertiary referral center with open access and objective assessment policies. <i>Digestive and Liver Disease</i> , 2018, 50, 37-41.	0.9	9
50	Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1302-1310.	2.3	16
51	Patients' perception of their involvement in shared treatment decision making: Key factors in the treatment of inflammatory bowel disease. <i>Patient Education and Counseling</i> , 2018, 101, 331-339.	2.2	32
52	Rural and urban disparities in the care of Canadian patients with inflammatory bowel disease: a population-based study. <i>Clinical Epidemiology</i> , 2018, Volume 10, 1613-1626.	3.0	48
53	Sex-Based Differences in Incidence of Inflammatory Bowel Diseases—Pooled Analysis of Population-Based Studies From Western Countries. <i>Gastroenterology</i> , 2018, 155, 1079-1089.e3.	1.3	155
54	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 141-154.	0.3	10

#	ARTICLE	IF	CITATIONS
55	A Study of Optimal Screening for Latent Tuberculosis in Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2695-2702.	2.3	5
56	Trends in Epidemiology of Pediatric Inflammatory Bowel Disease in Canada: Distributed Network Analysis of Multiple Population-Based Provincial Health Administrative Databases. <i>American Journal of Gastroenterology</i> , 2017, 112, 1120-1134.	0.4	241
57	Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1427-1434.e2.	4.4	187
58	Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis. <i>Gut</i> , 2017, 66, 1390-1397.	12.1	45
59	Rural and Urban Residence During Early Life is Associated with Risk of Inflammatory Bowel Disease: A Population-Based Inception and Birth Cohort Study. <i>American Journal of Gastroenterology</i> , 2017, 112, 1412-1422.	0.4	88
60	Inflammatory bowel disease and airway diseases. <i>World Journal of Gastroenterology</i> , 2016, 22, 7735.	3.3	39
61	Thiopurines in the Management of Crohn's Disease: Safety and Efficacy Profile in Patients with Normal TPMT Activity—A Retrospective Study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016, 1-7.	1.9	17
62	Mortality Trends in Crohn's Disease and Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 416-423.	1.9	48
63	Inflammatory bowel disease and risk of mortality in COPD. <i>European Respiratory Journal</i> , 2016, 47, 1357-1364.	6.7	29
64	Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus. <i>Gastroenterology</i> , 2015, 148, 1035-1058.e3.	1.3	323
65	Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. <i>Lancet</i> , The, 2015, 386, 1825-1834.	13.7	354
66	Increased incidence of inflammatory bowel disease in Québec residents with airway diseases. <i>European Respiratory Journal</i> , 2015, 45, 962-968.	6.7	50
67	Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: A systematic review and meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1632-1641.	1.3	83
68	Oral Corticosteroids and the Risk of Serious Infections in Patients With Elderly-Onset Inflammatory Bowel Diseases. <i>American Journal of Gastroenterology</i> , 2014, 109, 1795-1802.	0.4	107
69	Epidemiology of Inflammatory Bowel Disease in Québec. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1770-1776.	1.9	58
70	Decline in IBD Incidence in Québec. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1782-1783.	1.9	4
71	Consensus Statements on the Risk, Prevention, and Treatment of Venous Thromboembolism in Inflammatory Bowel Disease: Canadian Association of Gastroenterology. <i>Gastroenterology</i> , 2014, 146, 835-848.e6.	1.3	277
72	Occult Dysplasia in a Localized Giant Pseudopolyp in Crohn's Colitis: A Case Report. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2009, 23, 477-478.	1.7	23

#	ARTICLE	IF	CITATIONS
73	Preventing Postoperative Recurrence in Crohn's Disease With 6-Mercaptopurine and Azathioprine: Approaching the Cutting Edge. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 513-514.	1.9	5
74	Psychosocial Determinants of Relapse in Ulcerative Colitis: A Longitudinal Study. <i>American Journal of Gastroenterology</i> , 2003, 98, 2203-2208.	0.4	183
75	Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. <i>Nature Genetics</i> , 2001, 29, 223-228.	21.4	730
76	ANTI-TUMOR NECROSIS FACTOR Î±: CROHN'S DISEASE GUIDED MISSILE. <i>Inflammatory Bowel Diseases</i> , 1998, 4, 173-174.	1.9	0